MX2012000766A - Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina. - Google Patents

Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.

Info

Publication number
MX2012000766A
MX2012000766A MX2012000766A MX2012000766A MX2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A
Authority
MX
Mexico
Prior art keywords
prolyl hydroxylase
erythropoietin
compound
production
action
Prior art date
Application number
MX2012000766A
Other languages
English (en)
Spanish (es)
Inventor
Takashi Ito
Masahiro Yokota
Kazuhito Ueyama
Ikuo Mitani
Yosuke Ogoshi
Takuya Matsui
Masakazu Terashita
Dai Motoda
Takahiro Hotta
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2012000766A publication Critical patent/MX2012000766A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
MX2012000766A 2009-07-17 2010-07-16 Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina. MX2012000766A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009169565 2009-07-17
US27312709P 2009-07-30 2009-07-30
PCT/JP2010/062037 WO2011007856A1 (ja) 2009-07-17 2010-07-16 トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用

Publications (1)

Publication Number Publication Date
MX2012000766A true MX2012000766A (es) 2012-02-08

Family

ID=43449466

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000766A MX2012000766A (es) 2009-07-17 2010-07-16 Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.

Country Status (28)

Country Link
US (3) US8283465B2 (enExample)
EP (3) EP2455381B9 (enExample)
JP (9) JP5021797B2 (enExample)
KR (5) KR20260012830A (enExample)
CN (1) CN102471337B (enExample)
AR (1) AR077417A1 (enExample)
AU (1) AU2010271732B2 (enExample)
BR (1) BR112012001157A2 (enExample)
CA (1) CA2768505C (enExample)
CO (1) CO6430426A2 (enExample)
DK (1) DK2455381T5 (enExample)
ES (1) ES2477968T3 (enExample)
HR (1) HRP20140705T1 (enExample)
IL (1) IL217541A (enExample)
ME (1) ME01858B (enExample)
MX (1) MX2012000766A (enExample)
MY (1) MY160814A (enExample)
NZ (1) NZ598242A (enExample)
PE (1) PE20120629A1 (enExample)
PL (1) PL2455381T3 (enExample)
PT (1) PT2455381E (enExample)
RS (1) RS53499B1 (enExample)
RU (1) RU2538963C2 (enExample)
SG (1) SG178049A1 (enExample)
SI (1) SI2455381T1 (enExample)
SM (1) SMT201500122B (enExample)
TW (1) TWI485150B (enExample)
WO (1) WO2011007856A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2455381E (pt) * 2009-07-17 2014-06-24 Japan Tobacco Inc Composto de triazolopiridina e sua acção como inibidor da prolil-hidroxilase e indutor da produção de eritropoietina
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CN104936591B (zh) 2012-11-26 2018-05-29 国立大学法人东北大学 促红细胞生成素表达增强剂
NZ708605A (en) 2012-12-24 2016-07-29 Cadila Healthcare Ltd Novel quinolone derivatives
SMT202400092T1 (it) 2013-06-13 2024-05-14 Akebia Therapeutics Inc Composizioni e metodi per il trattamento dell'anemia
RU2534804C1 (ru) * 2013-08-05 2014-12-10 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ
SMT201800205T1 (it) 2013-10-03 2018-05-02 Kura Oncology Inc Inibitori di erk e metodi d'uso
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
JP2018039733A (ja) * 2014-12-22 2018-03-15 株式会社富士薬品 新規複素環誘導体
GB201504565D0 (en) * 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
EP4667059A3 (en) 2015-05-28 2026-04-08 Japan Tobacco Inc. Method for treating or preventing diabetic nephropathy
RU2752384C2 (ru) * 2016-11-25 2021-07-26 Джапан Тобакко Инк. Способ получения триазолопиридинового соединения
CA3062972C (en) 2017-05-09 2021-09-14 Kind Pharmaceutical Indolizine derivatives and their application in medicine
WO2019069973A1 (ja) * 2017-10-04 2019-04-11 日本たばこ産業株式会社 含窒素ヘテロアリール化合物およびその医薬用途
CN107739378A (zh) * 2017-11-14 2018-02-27 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
PL3808747T3 (pl) * 2018-09-13 2025-03-17 Kissei Pharmaceutical Co., Ltd. Związek imidazopirydynonowy
CN110105355B (zh) * 2019-05-24 2021-09-21 烟台大学 一种1,2,3-三唑-[1,5-a]并喹啉类化合物的制备方法
JP7566008B2 (ja) * 2020-03-11 2024-10-11 キッセイ薬品工業株式会社 イミダゾピリジノン化合物又はその塩の結晶
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN113387948B (zh) * 2021-02-06 2022-06-10 成都诺和晟泰生物科技有限公司 一种稠环杂芳基衍生物及其药物组合物和治疗方法及用途
EP4308120A4 (en) 2021-03-19 2024-11-27 Zydus Lifesciences Limited TREATMENT OF SICKLE CELL ANEMIA
WO2022251563A1 (en) 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN113582843A (zh) * 2021-09-09 2021-11-02 无锡捷化医药科技有限公司 一种5-氯-2-氟-3-羟基苯甲酸乙酯的制备方法
CN116496269B (zh) * 2021-12-02 2025-02-28 苏中药业集团股份有限公司 一种脯氨酰羟化酶抑制剂及其用途
CN114031619A (zh) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 一种图卡替尼中间体的制备方法
CN117327066A (zh) * 2022-06-30 2024-01-02 上海济煜医药科技有限公司 一种新多晶型、其制备方法及其用于制备药物的用途
EP4578855A1 (en) * 2022-09-19 2025-07-02 Suzhong Pharmaceutical Group Co., Ltd. Prolyl hydroxylase inhibitor and use thereof
TWI905781B (zh) * 2023-06-02 2025-11-21 大陸商蘇中藥業集團股份有限公司 脯胺醯羥化酶抑制劑及其用途
TW202506675A (zh) * 2023-08-08 2025-02-16 美商富曼西公司 用於防治和對抗無脊椎有害生物的連接的雙環化合物
WO2025087207A1 (zh) 2023-10-24 2025-05-01 杭州安道药业有限公司 含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用
CN117486878B (zh) * 2023-10-27 2026-05-05 扬州市普林斯医药科技有限公司 一种恩那司他的制备方法
WO2025137158A1 (en) * 2023-12-19 2025-06-26 Akebia Therapeutics, Inc. Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as phd inhibitor compounds, compositions, and methods of use
CN119818492B (zh) * 2024-02-05 2026-01-30 深圳信立泰药业股份有限公司 化合物在制备治疗非髓系恶性肿瘤患者的贫血药物中的应用
WO2025167739A1 (zh) * 2024-02-05 2025-08-14 深圳信立泰药业股份有限公司 化合物在制备预防和/或治疗高原病的药物中的应用
CN119039291A (zh) * 2024-09-09 2024-11-29 南京药坦生物科技有限公司 一种恩那度司他中间体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
BR0213172A (pt) * 2001-10-08 2004-09-14 Hoffmann La Roche Amida do ácido 8-amino-[1,2,4]triazolo[1,5-a]piridina-6-carboxìlico
WO2005014533A2 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
EP1776338A1 (en) * 2004-08-05 2007-04-25 F. Hoffmann-Roche AG Indole, indazole or indoline derivatives
FR2889383A1 (fr) * 2005-08-01 2007-02-02 France Telecom Procede et dispositif de detection pour systeme mimo, systeme mimo, programme et support d'information
AR059733A1 (es) * 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
WO2007136990A2 (en) * 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JO2934B1 (en) * 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
NZ601730A (en) * 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
US20100035756A1 (en) 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
TW200845991A (en) * 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
EP2142509B1 (en) * 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
WO2008137084A2 (en) 2007-05-04 2008-11-13 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
EP2460787A1 (en) 2007-07-03 2012-06-06 Astellas Pharma Inc. Amide compounds and their use as PGE2 antagonists.
US20100305154A1 (en) * 2007-11-30 2010-12-02 Glaxosmithkline Llc Prolyl Hydroxylase Inhibitors
WO2009073497A2 (en) * 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009126624A1 (en) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
WO2009134850A1 (en) * 2008-04-30 2009-11-05 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
AU2009251324A1 (en) 2008-05-29 2009-12-03 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
SG172206A1 (en) 2008-12-19 2011-07-28 Leo Pharma As Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
PT2455381E (pt) * 2009-07-17 2014-06-24 Japan Tobacco Inc Composto de triazolopiridina e sua acção como inibidor da prolil-hidroxilase e indutor da produção de eritropoietina

Also Published As

Publication number Publication date
NZ598242A (en) 2013-09-27
KR20120051704A (ko) 2012-05-22
SMT201500122B (it) 2015-07-09
KR20170018105A (ko) 2017-02-15
JP2016040321A (ja) 2016-03-24
EP2455381B9 (en) 2014-10-22
CO6430426A2 (es) 2012-04-30
JP2011037841A (ja) 2011-02-24
RU2538963C2 (ru) 2015-01-10
AU2010271732B2 (en) 2016-08-25
EP2455381B1 (en) 2014-05-28
SG178049A1 (en) 2012-03-29
JP2022126843A (ja) 2022-08-30
CA2768505C (en) 2018-06-12
CN102471337B (zh) 2014-12-10
PL2455381T3 (pl) 2014-10-31
KR101850661B1 (ko) 2018-04-19
EP3594213A1 (en) 2020-01-15
AR077417A1 (es) 2011-08-24
WO2011007856A1 (ja) 2011-01-20
TW201105671A (en) 2011-02-16
AU2010271732A1 (en) 2012-03-08
JP2024091878A (ja) 2024-07-05
US20130096155A1 (en) 2013-04-18
JP2017214404A (ja) 2017-12-07
DK2455381T3 (da) 2014-07-21
CN102471337A (zh) 2012-05-23
CA2768505A1 (en) 2011-01-20
ES2477968T3 (es) 2014-07-18
IL217541A0 (en) 2012-02-29
ME01858B (me) 2014-12-20
JP2015003933A (ja) 2015-01-08
EP2455381A1 (en) 2012-05-23
IL217541A (en) 2014-07-31
HK1168346A1 (en) 2012-12-28
EP2746282A1 (en) 2014-06-25
JP6434575B2 (ja) 2018-12-05
MY160814A (en) 2017-03-31
PE20120629A1 (es) 2012-05-30
ES2477968T9 (es) 2014-11-13
KR20260012830A (ko) 2026-01-27
KR20180042443A (ko) 2018-04-25
KR20230165366A (ko) 2023-12-05
US8283465B2 (en) 2012-10-09
PT2455381E (pt) 2014-06-24
RS53499B1 (sr) 2015-02-27
BR112012001157A2 (pt) 2016-02-23
US20110077267A1 (en) 2011-03-31
EP2455381A4 (en) 2012-12-12
RU2012105467A (ru) 2013-08-27
SI2455381T1 (sl) 2014-08-29
HRP20140705T1 (hr) 2014-09-12
KR101706803B1 (ko) 2017-02-14
JP5021797B2 (ja) 2012-09-12
DK2455381T5 (en) 2015-02-09
US20160145254A1 (en) 2016-05-26
JP2012144571A (ja) 2012-08-02
JP2019019144A (ja) 2019-02-07
TWI485150B (zh) 2015-05-21
JP2020111612A (ja) 2020-07-27

Similar Documents

Publication Publication Date Title
CO6430426A2 (es) Compuestos de triazolopiridina, y su accion comominhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina
AR121611A2 (es) Inhibidores de glucosilceramida sintasa
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
JO3204B1 (ar) 4- أريل-n- فنيل-5،3،1- ترايازين-2- أمينات محتوية على مجموعة سلفوكسيمين
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
TR201816379T4 (tr) DNA-PK inhibitörleri.
PH12013502059A1 (en) Pyrrolotriazinone derivatives as p13k inhibitors
BR112014004219A2 (pt) pirano[3,2-d][1,3]tiazol como inibidores de glicosidase
JO3453B1 (ar) مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
AU2012214029A8 (en) Rorgammat inhibitors
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
NZ707859A (en) Inhibitors of sodium glucose cotransporter 1
ECSP11011048A (es) Inhibidores de cinasa akt y p70 s6
CU20150020A7 (es) Composición farmacéutica recubierta que contiene regorafenib
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
IN2015DN01151A (enExample)
CR20140553A (es) Compuestos de fenoxietil piperidina
BR112012004851B8 (pt) uso de um derivado de tiazol
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
MX2013012233A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
UY32652A (es) Piperidinas sustituidas

Legal Events

Date Code Title Description
FG Grant or registration